CN Patent

CN105669864B — 抗人程序性死亡受体1抗体及其制备方法和用途

Assigned to Jushi biopharmaceutical Co.,Ltd. · Expires 2018-10-16 · 8y expired

What this patent protects

本发明涉及抗人程序性死亡受体1抗体及其制备方法和用途。具体而言，本发明涉及利用天然抗体库筛选平台筛选获得的一株新型抗人程序性死亡受体1抗体，其能够特异性识别人PD‑1分子，阻断PD‑1/PD‑L1以及PD‑1/PD‑L2相互作用，提高免疫应答水平。

USPTO Abstract

本发明涉及抗人程序性死亡受体1抗体及其制备方法和用途。具体而言，本发明涉及利用天然抗体库筛选平台筛选获得的一株新型抗人程序性死亡受体1抗体，其能够特异性识别人PD‑1分子，阻断PD‑1/PD‑L1以及PD‑1/PD‑L2相互作用，提高免疫应答水平。

Drugs covered by this patent

Patent Metadata

Patent number
CN105669864B
Jurisdiction
CN
Classification
—
Expires
2018-10-16
Drug substance claim
No
Drug product claim
No
Assignee
Jushi biopharmaceutical Co.,Ltd.
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.